Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.
Identifieur interne : 000A02 ( Main/Exploration ); précédent : 000A01; suivant : 000A03Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.
Auteurs : RBID : pubmed:21645641English descriptors
- KwdEn :
- Animals, Cell Line, Tumor, Drug Delivery Systems, Inhibitory Concentration 50, Iridium Radioisotopes, Liposomes (administration & dosage), Liposomes (chemistry), Mice, Mice, Nude, Micelles, Nanoparticles (administration & dosage), Nanoparticles (therapeutic use), Octreotide (administration & dosage), Octreotide (analogs & derivatives), Octreotide (therapeutic use), Pancreatic Neoplasms (drug therapy), Pentetic Acid (chemistry), Phosphatidylethanolamines (chemistry), Polyethylene Glycols (chemistry), Rats, Rats, Inbred Lew, Tissue Distribution, Tomography, Emission-Computed, Single-Photon, Transplantation, Heterologous.
- MESH :
- chemical , administration & dosage : Liposomes, Octreotide.
- chemical , analogs & derivatives : Octreotide.
- chemical , chemistry : Liposomes, Pentetic Acid, Phosphatidylethanolamines, Polyethylene Glycols.
- chemical , therapeutic use : Octreotide.
- chemical : Iridium Radioisotopes, Micelles.
- administration & dosage : Nanoparticles.
- drug therapy : Pancreatic Neoplasms.
- therapeutic use : Nanoparticles.
- Animals, Cell Line, Tumor, Drug Delivery Systems, Inhibitory Concentration 50, Mice, Mice, Nude, Rats, Rats, Inbred Lew, Tissue Distribution, Tomography, Emission-Computed, Single-Photon, Transplantation, Heterologous.
Abstract
Radiolabeled PEGylated liposomal nanoparticles (NPs) open new possibilities for a variety of applications including diagnosis, drug delivery, targeted therapy, and monitoring treatment effects. Here we describe the characterization of liposomal NPs (liposomes and micelles) derivatized with the somatostatin analogue tyrosine-3-octreotide as a proof of concept for tumor targeting. NPs were radiolabeled with indium-111, and targeting properties were evaluated in vitro on rat pancreatic tumor cells (AR42J), demonstrating specific binding and IC(50) values in the low nanomolar range. Biodistribution studies were performed in Lewis rats and compared to single-photon emission computed tomography images. Moderate tumor uptake was found in xenografted nude mice (<2.5% ID/g tissue) as compared to control. Micelles and liposomes revealed comparable pharmacokinetics and targeting properties. This study provides insight into tumor-targeting characteristics of peptide-derivatized liposomal NPs and can serve as a basis for further improvement of these constructs.
DOI: 10.1016/j.nano.2011.04.012
PubMed: 21645641
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.</title><author><name sortKey="Helbok, Anna" uniqKey="Helbok A">Anna Helbok</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Department of Nuclear Medicine, Innsbruck Medical University, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Nuclear Medicine, Innsbruck Medical University</wicri:regionArea></affiliation></author><author><name sortKey="Rangger, Christine" uniqKey="Rangger C">Christine Rangger</name></author><author><name sortKey="Von Guggenberg, Elisabeth" uniqKey="Von Guggenberg E">Elisabeth von Guggenberg</name></author><author><name sortKey="Saba Lepek, Matthias" uniqKey="Saba Lepek M">Matthias Saba-Lepek</name></author><author><name sortKey="Radolf, Thorsten" uniqKey="Radolf T">Thorsten Radolf</name></author><author><name sortKey="Thurner, Gudrun" uniqKey="Thurner G">Gudrun Thurner</name></author><author><name sortKey="Andreae, Fritz" uniqKey="Andreae F">Fritz Andreae</name></author><author><name sortKey="Prassl, Ruth" uniqKey="Prassl R">Ruth Prassl</name></author><author><name sortKey="Decristoforo, Clemens" uniqKey="Decristoforo C">Clemens Decristoforo</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1016/j.nano.2011.04.012</idno><idno type="RBID">pubmed:21645641</idno><idno type="pmid">21645641</idno><idno type="wicri:Area/Main/Corpus">001346</idno><idno type="wicri:Area/Main/Curation">001346</idno><idno type="wicri:Area/Main/Exploration">000A02</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cell Line, Tumor</term><term>Drug Delivery Systems</term><term>Inhibitory Concentration 50</term><term>Iridium Radioisotopes</term><term>Liposomes (administration & dosage)</term><term>Liposomes (chemistry)</term><term>Mice</term><term>Mice, Nude</term><term>Micelles</term><term>Nanoparticles (administration & dosage)</term><term>Nanoparticles (therapeutic use)</term><term>Octreotide (administration & dosage)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (therapeutic use)</term><term>Pancreatic Neoplasms (drug therapy)</term><term>Pentetic Acid (chemistry)</term><term>Phosphatidylethanolamines (chemistry)</term><term>Polyethylene Glycols (chemistry)</term><term>Rats</term><term>Rats, Inbred Lew</term><term>Tissue Distribution</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Transplantation, Heterologous</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Liposomes</term><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Liposomes</term><term>Pentetic Acid</term><term>Phosphatidylethanolamines</term><term>Polyethylene Glycols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Iridium Radioisotopes</term><term>Micelles</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line, Tumor</term><term>Drug Delivery Systems</term><term>Inhibitory Concentration 50</term><term>Mice</term><term>Mice, Nude</term><term>Rats</term><term>Rats, Inbred Lew</term><term>Tissue Distribution</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Transplantation, Heterologous</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Radiolabeled PEGylated liposomal nanoparticles (NPs) open new possibilities for a variety of applications including diagnosis, drug delivery, targeted therapy, and monitoring treatment effects. Here we describe the characterization of liposomal NPs (liposomes and micelles) derivatized with the somatostatin analogue tyrosine-3-octreotide as a proof of concept for tumor targeting. NPs were radiolabeled with indium-111, and targeting properties were evaluated in vitro on rat pancreatic tumor cells (AR42J), demonstrating specific binding and IC(50) values in the low nanomolar range. Biodistribution studies were performed in Lewis rats and compared to single-photon emission computed tomography images. Moderate tumor uptake was found in xenografted nude mice (<2.5% ID/g tissue) as compared to control. Micelles and liposomes revealed comparable pharmacokinetics and targeting properties. This study provides insight into tumor-targeting characteristics of peptide-derivatized liposomal NPs and can serve as a basis for further improvement of these constructs.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21645641</PMID><DateCreated><Year>2012</Year><Month>01</Month><Day>09</Day></DateCreated><DateCompleted><Year>2012</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-9642</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nanomedicine : nanotechnology, biology, and medicine</Title><ISOAbbreviation>Nanomedicine</ISOAbbreviation></Journal><ArticleTitle>Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.</ArticleTitle><Pagination><MedlinePgn>112-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nano.2011.04.012</ELocationID><Abstract><AbstractText Label="UNLABELLED">Radiolabeled PEGylated liposomal nanoparticles (NPs) open new possibilities for a variety of applications including diagnosis, drug delivery, targeted therapy, and monitoring treatment effects. Here we describe the characterization of liposomal NPs (liposomes and micelles) derivatized with the somatostatin analogue tyrosine-3-octreotide as a proof of concept for tumor targeting. NPs were radiolabeled with indium-111, and targeting properties were evaluated in vitro on rat pancreatic tumor cells (AR42J), demonstrating specific binding and IC(50) values in the low nanomolar range. Biodistribution studies were performed in Lewis rats and compared to single-photon emission computed tomography images. Moderate tumor uptake was found in xenografted nude mice (<2.5% ID/g tissue) as compared to control. Micelles and liposomes revealed comparable pharmacokinetics and targeting properties. This study provides insight into tumor-targeting characteristics of peptide-derivatized liposomal NPs and can serve as a basis for further improvement of these constructs.</AbstractText><AbstractText Label="FROM THE CLINICAL EDITOR" NlmCategory="UNASSIGNED">The authors investigated tumor-targeting characteristics of peptide-derivatized liposomal NPs. Similar radiolabeled PEGylated liposomal NPs open new possibilities for a variety of applications including diagnosis, drug delivery, targeted therapy, and treatment monitoring.</AbstractText><CopyrightInformation>2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Helbok</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Affiliation>Clinical Department of Nuclear Medicine, Innsbruck Medical University, Austria.</Affiliation></Author><Author ValidYN="Y"><LastName>Rangger</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>von Guggenberg</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Saba-Lepek</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Radolf</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Thurner</LastName><ForeName>Gudrun</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Andreae</LastName><ForeName>Fritz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Prassl</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Decristoforo</LastName><ForeName>Clemens</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nanomedicine</MedlineTA><NlmUniqueID>101233142</NlmUniqueID><ISSNLinking>1549-9634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iridium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Micelles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Phosphatidylethanolamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>103667-46-5</RegistryNumber><NameOfSubstance>3-Tyr-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>20255-95-2</RegistryNumber><NameOfSubstance>1,2-dimyristoylphosphatidylethanolamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iridium Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liposomes</DescriptorName><QualifierName MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Micelles</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Phosphatidylethanolamines</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats, Inbred Lew</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Transplantation, Heterologous</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S1549-9634(11)00174-2</ArticleId><ArticleId IdType="doi">10.1016/j.nano.2011.04.012</ArticleId><ArticleId IdType="pubmed">21645641</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21645641
|texte= Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21645641" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |